Rusan Pharma Invests 300 Crores in New API Facility in MP’s Pithampur

Rusan Pharma, a pharmaceutical company, on Saturday launched a new active pharmaceutical ingredients (API) facility in Pithampur, Madhya Pradesh.

This facility will produce 400 tons of active pharmaceutical substances annually and is expected to create more than 300 jobs. The company has invested Rs 300 crore in the facility, located in the Pithampur Special Economic Zone (SEZ).

The new facility will augment Rusan Pharma’s existing API capacity, aiming to supply critical APIs to meet the increasing demand for its addiction treatment and pain management products in India and internationally.

The company is known for developing innovative products such as sublingual buprenorphine and buprenorphine-naloxone sublingual tablets for the treatment of drug abuse, apomorphine injections for the treatment of Parkinson’s and indigenous formulations of fentanyl, buprenorphine and lidocaine transdermal patches for moderate to severe pain. In addition, they produce transdermal nicotine patches for smoking cessation.

Kunal Saxena, Managing Director, Rusan Pharma, commented, “With an investment of approximately Rs 300 crore in two phases, this new API facility will expand our current API manufacturing capacity from 40 tonnes in Ankleshwar to 400 tonnes in Pithampur. Our new factory features five modular API production blocks with dedicated suites for completed API production.”

The company stated that current Good Manufacturing Practice (GMP) approvals for its APIs and finished product facilities have the capacity to meet 90 percent of global demand.

Rusan Pharma has GMP approvals from several authorities including Health Canada, Australia’s Therapeutic Goods Administration (TGA), South African Health Products Regulatory Authority (SAPHRA), European Union (EU), United Arab Emirates (UAE) and Russia.